Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Express Scripts

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Rigosertib

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Rigosertib?

Rigosertib is an investigational drug.

There have been 28 clinical trials for Rigosertib. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2010.

The most common disease conditions in clinical trials are Syndrome, Preleukemia, and Myelodysplastic Syndromes. The leading clinical trial sponsors are Onconova Therapeutics, Inc., M.D. Anderson Cancer Center, and Academic Oncology Gastrointestinal Cancer Consortium (AGICC).

There are fourteen US patents protecting this investigational drug and eighty-one international patents.

Recent Clinical Trials for Rigosertib
Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCCOnconova Therapeutics, Inc.Early Phase 1
Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCCThomas Jefferson UniversityEarly Phase 1
Rigosertib for RDEB-SCCProf. Johann BauerPhase 1/Phase 2

See all Rigosertib clinical trials

Clinical Trial Summary for Rigosertib

Top disease conditions for Rigosertib
Top clinical trial sponsors for Rigosertib

See all Rigosertib clinical trials

US Patents for Rigosertib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Rigosertib   Start Trial Formulations with enhanced stability and bioavailability for administration of (E)-2,6-dialkoxystyryl 4-substituted benzylsulfones ONCONOVA THERAPEUTICS, INC. (Newtown, PA)   Start Trial
Rigosertib   Start Trial Substituted alkyl diaryl derivatives, methods of preparation and uses TEMPLE UNIVERSITY--Of The Commonwealth System of Higher Education (Philadelphia, PA)   Start Trial
Rigosertib   Start Trial 2,4,6-trialkoxystryl aryl sulfones, sulfonamides and carboxamides, and methods of preparation and use Temple University--Of The Commonwealth System Of Higher Education (Philadelphia, PA)   Start Trial
Rigosertib   Start Trial Amino-substituted (E)-2,6-dialkoxystyryl 4-substituted-benzylsulfones for treating proliferative disorders Temple University - Of the Commonwealth System of Higher Education (Philadelphia, PA) Onconova Therapeutics, Inc. (Newtown, PA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Rigosertib

Drugname Country Document Number Estimated Expiration Related US Patent
Rigosertib Argentina 109503 2037-04-13   Start Trial
Rigosertib Australia 2018253291 2037-04-13   Start Trial
Rigosertib Canada 3058664 2037-04-13   Start Trial
Rigosertib Taiwan 201836597 2037-04-13   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.